Recently, Moreno L et al. [46] described that in vitro treatment of several human myeloma cell lines with another anti-CD38 mAb, isatuximab, induces CD38 internalization without its release from MM cell surface [46]. Here, CD38 is linked to Miyoshi myopathy.